Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KAREN H LU and SAMUEL MOK.
KAREN H LU
Connection Strength
2.976
SAMUEL MOK
  1. The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila). 2009 Sep; 2(9):773-5.
    View in: PubMed
    Score: 0.348
  2. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses. Cancers (Basel). 2024 Feb 20; 16(5).
    View in: PubMed
    Score: 0.237
  3. Ryanodine receptor 1-mediated Ca2+ signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes. J Exp Clin Cancer Res. 2022 Aug 11; 41(1):242.
    View in: PubMed
    Score: 0.213
  4. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun. 2020 07 15; 11(1):3546.
    View in: PubMed
    Score: 0.185
  5. Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers (Basel). 2020 Mar 14; 12(3).
    View in: PubMed
    Score: 0.180
  6. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. Cancers (Basel). 2020 Jan 02; 12(1).
    View in: PubMed
    Score: 0.178
  7. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer. J Natl Cancer Inst. 2019 03 01; 111(3):272-282.
    View in: PubMed
    Score: 0.168
  8. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol. 1999 Jan; 93(1):34-7.
    View in: PubMed
    Score: 0.166
  9. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers (Basel). 2018 Nov 22; 10(12).
    View in: PubMed
    Score: 0.165
  10. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res. 1998 Jun 01; 58(11):2328-30.
    View in: PubMed
    Score: 0.159
  11. Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers (Basel). 2018 Feb 21; 10(2).
    View in: PubMed
    Score: 0.156
  12. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res. 1997 Feb 01; 57(3):387-90.
    View in: PubMed
    Score: 0.145
  13. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016 Mar 29; 7:11150.
    View in: PubMed
    Score: 0.137
  14. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer. 2014 Nov 15; 120(22):3457-68.
    View in: PubMed
    Score: 0.122
  15. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer Prev Res (Phila). 2011 Mar; 4(3):463-70.
    View in: PubMed
    Score: 0.096
  16. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res. 2003 Oct 15; 9(13):4782-91.
    View in: PubMed
    Score: 0.058
  17. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436. Cancers (Basel). 2021 Feb 04; 13(4).
    View in: PubMed
    Score: 0.048
  18. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers (Basel). 2020 Aug 27; 12(9).
    View in: PubMed
    Score: 0.047
  19. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res. 2017 Aug 01; 23(15):4473-4481.
    View in: PubMed
    Score: 0.037
  20. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One. 2013; 8(12):e81859.
    View in: PubMed
    Score: 0.029
  21. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol. 2011 Jun; 35(6):904-12.
    View in: PubMed
    Score: 0.025
  22. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol. 2010 Oct; 177(4):1611-7.
    View in: PubMed
    Score: 0.023
  23. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009 Sep; 22(9):1243-50.
    View in: PubMed
    Score: 0.021
  24. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005 Nov 15; 65(22):10602-12.
    View in: PubMed
    Score: 0.017
  25. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005 Nov; 99(2):267-77.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.